Education
About Us
Working with TipRanks
Follow Us
Cibus (CBUS)
NASDAQ:CBUS
CBUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $6.10
Previous CloseN/A
Volume64.89K
Average Volume (3M)189.23K
Market Cap
$80.84M
Enterprise Value$275.23M
Total Cash (Recent Filing)$36.46M
Total Debt (Recent Filing)$35.42M
Price to Earnings (P/E)―
Beta3.30
Next Earnings
Nov 06, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding52,540,527
10 Day Avg. Volume198,858
30 Day Avg. Volume189,233
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.40
Enterprise Value/Revenue56.80
Enterprise Value/Gross Profit56.80
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$20.00Price Target Upside1298.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Cost ManagementCibus reported a reduction in operating expenses driven by management’s cost reduction efforts, which is part of a restructuring initiative aimed at focusing on core projects.
Market ExpansionThe U.S. Department of Agriculture's designation of Cibus’ HT2 herbicide-tolerance trait in canola as not regulated could facilitate market access.
Revenue GrowthManagement expects the commercialization of Cibus' sustainable ingredients and biofragrance products to generate significant revenues, with expectations of material expansion in the future.
Bears Say
Financial PerformanceCibus announced a quarterly net loss, highlighting ongoing financial challenges despite improvements.
Investor SentimentMaintaining the timeline for their core gene-edited trait and sustainable ingredient opportunities is crucial, as delays could impact investor sentiment.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.20 and its highest was $6.10 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $80.84M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Nov 06, 2025 which is in 28 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Aug 14, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.602 by -$0.008.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.44.
How many shares outstanding does Cibus have?
Cibus has 52,540,527 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.602. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
Cibus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (1298.60% Upside)
$20.00 (1298.60% Upside)
Blogger Sentiment
Bullish
CBUS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.72%
12-Months-Change
Fundamentals
Return on Equity
-160.72%
Trailing 12-Months
Asset Growth
-37.44%
Trailing 12-Months
Company Description
Cibus
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
CBUS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the commercialization of rice herbicide traits and biofragrance products, alongside positive regulatory developments. However, challenges include a delay in the EU regulatory process and a notable net loss. The company's strategic focus on cost reduction and capital allocation is aimed at managing cash usage effectively.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$20.00
▲(1298.60% Upside)
Technical Analysis
Avalo Therapeutics
―
Inozyme Pharma
―
Kronos Bio
―
Gain Therapeutics
―
Metagenomi, Inc.
―
Ownership Overview
32.65% Insiders
7.26% Mutual Funds
4.88% Other Institutional Investors
53.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---